Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
Zacks Investment Research on MSN
Novavax grants license for use of Matrix-M adjuvant to Pfizer
Novavax NVAX announced a non-exclusive license agreement with Pfizer PFE, granting the latter access to its proprietary ...
InvestorsHub on MSN
Novavax shares gain after Matrix-M adjuvant licensing deal with Pfizer
Novavax (NASDAQ:NVAX) shares climbed about 5% on Tuesday after the biotech group disclosed a non-exclusive licensing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback